| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/09/2024 | 22:05 | Business Wire | Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 20/08/2024 | 17:26 | Business Wire | Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 14/08/2024 | 21:12 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 14/08/2024 | 11:56 | IH Market News | UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 09/08/2024 | 12:05 | Business Wire | Amneal Reports Second Quarter 2024 Financial Results | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 07/08/2024 | 22:45 | Business Wire | Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 29/07/2024 | 22:05 | Business Wire | Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 11/07/2024 | 22:05 | Business Wire | Amneal to Report Second Quarter 2024 Results on August 9, 2024 | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 09/07/2024 | 22:05 | Business Wire | Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 01/07/2024 | 14:00 | Business Wire | Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab) | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 01/07/2024 | 14:00 | Business Wire | Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 28/06/2024 | 14:00 | Business Wire | Amneal Releases 2023 Environmental, Social and Governance Report | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 05/06/2024 | 14:00 | Business Wire | Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 22/05/2024 | 22:05 | Business Wire | Amneal to Participate at Upcoming Investor Conference | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 22/05/2024 | 22:05 | Business Wire | Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 14/05/2024 | 22:45 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 07/05/2024 | 22:18 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 03/05/2024 | 12:00 | Business Wire | Amneal Reports First Quarter 2024 Financial Results | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 24/04/2024 | 14:00 | Business Wire | Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 16/04/2024 | 14:00 | Business Wire | Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 10/04/2024 | 14:00 | Business Wire | Amneal to Report First Quarter 2024 Results on May 3, 2024 | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 28/03/2024 | 21:05 | Business Wire | Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 25/03/2024 | 21:05 | Business Wire | Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 22/03/2024 | 13:01 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 22/03/2024 | 13:01 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 01/03/2024 | 12:00 | Business Wire | Amneal Reports Fourth Quarter and Full Year 2023 Financial Results | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 27/02/2024 | 14:00 | Business Wire | Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203 | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 08/02/2024 | 22:05 | GlobeNewswire Inc. | Amneal Announces Complete Response Resubmission for IPX203 New Drug Application | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 31/01/2024 | 22:05 | Business Wire | Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024 | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |
| 10/01/2024 | 14:00 | Business Wire | Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension | NYSE:AMRX | Amneal Pharmaceuticals Holding Co |